Pharmaceutical dry powder aerosols: Correlation of powder properties with dose delivery and implications for pharmacodynamic effect

Pharmaceutical Research

Volumn 16, Issue 6, 1999, Pages 828-834

  Concessio, Neville M ^a,b   VanOort, Michiel M ^d   Knowles, Michael R ^c   Hickey, Anthony J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b BAYER CORPORATION   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

Bronchodilation; Capacity dimension; Dispersion; Dry powder aerosols; Impact force separation; Pharmacodynamic effect; Powder flow

Indexed keywords

BRONCHODILATING AGENT; EXCIPIENT; LACTOSE; MALTODEXTRIN; SALBUTAMOL SULFATE;

AEROSOL; AIRFLOW; ANIMAL MODEL; ARTICLE; BRONCHODILATATION; BRONCHOSPASM; CHEMICAL ANALYSIS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRY POWDER; GUINEA PIG; INHALATIONAL DRUG ADMINISTRATION; MATHEMATICAL ANALYSIS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

AEROSOLS; ALBUTEROL; ANIMALS; BRONCHODILATOR AGENTS; FEMALE; GUINEA PIGS; PARTICLE SIZE; POWDERS;

EID: 0033019160     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018865717374     Document Type: Article

References (30)

1. 1. A. R. Clark. Medical aerosol inhalers: past, present and future. Aerosol Sci. and Tech. 22:374-391 (1995).
2. 2. S. P. Newman and S. W. Clarke. Therapeutic aerosols, I, physical and practical considerations. Thorax. 38:881-886 (1983).
3. 3. G. Scheuch and W. Stahlhofen. Deposition and dispersion of aerosols in the airways of the human respiratory tract: the effects of particle size. Exp. Lung Rex. 18:343-358 (1992).
4. 4. S. P. Newman. In S. W. Clark and D. Pavia (eds), Aerosols and the Lung: Clinical and Experimental Aspects, Butterworths, London, 1984, pp. 197-224.
5. 5. P. J. Davies, G. W. Hanlon, and A. J. Molyneux. An investigation into the deposition of inhalation aerosol particles as a function of air flow rate in a modified Kirk lung. J. Pharm. Pharmacol. 28:908-911 (1976).
6. 6. J. Visser. An invited review: Van der Waals and other cohesive forces affecting powder fluidization. Powder Tech. 58:1-10 (1989).
7. 7. A. J. Hickey, N. M. Concessio, M. M. VanOort, and R. M. Platz. Factors influencing the dispersion of dry powders as aerosols. Pharm. Tech. 18:58-64 (1994).
8. 8. N.M. Concessio. Dynamic properties of pharmaceutical powders and their impact on aerosol dispersion, thesis, University of North Carolina at Chapel Hill (1997).
9. 9. A. J. Hickey and N. M. Concessio. Flow properties of selected pharmaceutical powders from a vibrating spatula. Part. Part. Syst. Charac. 11:457-462 (1994).
10. 10. P. Speiser and R. Tawashi. Misch Wirkung Pharmazeutisch ver wendeter Pulvermischer. Pharm. Acta. Helv. 37:529-543 (1962).
11. 11. J. T. Carstensen. Pharmaceutical Principles of Solid Dosage Forms, Technomic Publishing Company, Lancaster, 1993.
12. 12. A. J. Hickey and N. M. Concessio. Chaos in rotating lactose powder beds. Particulate Sci. and Tech. 14:15-25 (1996).
13. 13. N. M. Concessio and A. J. Hickey. Analysis of the patterns of particle dispersion from a dry powder inhaler. Pharm. Tech. 20:50-62 (1996).
14. 14. A. J. Hickey and N. M. Concessio. Descriptors of irregular particle morphology and powder properties. Adv. Drug Del. Rev. 26:29-40 (1997).
15. 15. F. C. Moon. Chaotic and Fractal Dynamics, John Wiley and Sons, New York, 1992.
16. 16. D. Ruelte. Strange attractors. Math Intelligencer 2:126-137 (1980).
17. 17. B. Kaye. Chaos and Complexity: Discovering the Surprising Patterns of Science and Technology, VCH Publishers, New York, 1993, pp. 64-70.
18. 18. H. Froehling, J. P. Crutchfield, D. Farmer, N. H. Packard, and R. Shaw. On determining the dimension of chaotic flows. Physica. 30:605-617 (1981).
19. 19. J. D. Farmer, E. Ott, and J. A. Yorke. The dimension of chaotic attractors. Physica. 7D:153-180 (1983).
20. 20. A. Otsuka, K. Kida, K. Danjo, and H. Sunada. Measurement of the adhesive force between particles of powdered organic materials and a glass substrate by means of the impact separation method, I, effect of temperature. Chem. Pharm. Bull. 31:4483-4488 (1983).
21. 21. B. A. Webber, J. V. Collins, and M. A. Braithewaite. Sever acute asthma: a comparison of three methods of inhaling Salbutamol. Br. J. Dis. Chest. 76:69-74 (1982).
22. 22. B. S. Cohen. The first 40 years. In J. P. Lodge and T. L. Chan (eds). Cascade Impactor, Sampling and Data Analysis, American Industrial Hygiene Assoc., Ohio, 1986.
23. 23. J. P. Mitchell, P. A. Costa, and S. Waters. An assessment of an Andersen Mark-II cascade impactor. J. Aerosol Sci. 19:231-221 (1988).
24. 24. R. M. Auty, K. Brown, M. Neale, and P. D. Snashall. Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler. Br. J. Dis. Chest. 81:371-380 (1987).
25. 25. M. VanOort, B. Downey, and W. Roberts. Verification of operating the Andersen cascade impactor at different flow rates. Pharm. Forum. 22:2211-2215 (1996).
26. 26. N. M. Concessio, R. Jager-Waldau, and A. J. Hickey. Aerosol delivery from an active emission multi-single dose dry powder inhaler. Particulate Sci. Tech. 15:51-63 (1997).
27. 27. S. Desquand, J. Lefort, C. Dumarey, and B. B. Vargaftig. The booster injection of antigen during active sensitization of guinea pig modifies the anti-anaphylactic activity of the PAF antagonist WEB 2086. Br. J. Pharmacol. 100:217-222 (1990).
28. 28. D. A. Handley, J. J. DeLeo, and A. M. Havill. Induction of aerosol allergen of sustained and nonspecific IgE-mediated airway hyperactivity in the guinea pig. Agents Actions. 37:201-203 (1992).
29. 29. H. Konzett and R. Roessler. Versuchsanordnung zu untersuchungen an der Bornchialmuskulatur. Naunyn Schmiedeberg. Arch. Exp. Path. Pharmakol. 195:71-74 (1940).
30. 30. J. S. Franzone, R. Cirillo, and P. Biffignandi. Doxofylline exerts a prophylactic effect against bronchoconstriction and pleurisy induced by PAF. Eur. J. Pharmacol. 165:269-277 (1989).